Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mons – page 22

640 clinical trials in Mons, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mons at a glance
640
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

640 trials in Mons

Open in trial search

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Crohn's disease

Not yet recruiting

Evaluation of Upadacitinib for Reducing Ileal Strictures in Patients with Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:UZ Leuven

Breast cancer

Not yet recruiting

ImmunoPET with 89Zr‑trastuzumab to predict response to trastuzumab deruxtecan in patients with locally advanced or metastatic breast cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:89Zr-SucDf-Trastuzumab
  • Sponsor:Unicancer

Second‑line ivonescimab plus chemotherapy drug combination versus bevacizumab in patients with metastatic colorectal cancer without liver metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Unicancer

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mons

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of combination therapies with BNT327 and investigations into both small cell and non-small cell variants. Additional research covers breast cancer and cervical cancer treatments.

  • Non-small cell lung cancer therapy optimization
  • Advanced solid tumors treatment
  • Lymphoma treatment innovations

Studies aim to improve survival rates and treatment effectiveness through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into coronary artery disease and post-stroke treatments, evaluating new antiplatelet therapies and innovative stent technologies. Studies focus on reducing cardiovascular events and improving patient outcomes.

  • Acute coronary syndrome management
  • Stroke prevention strategies
  • Antiplatelet therapy optimization

Investigations aim to enhance treatment protocols and reduce cardiovascular complications.

03 Autoimmune Conditions

Groundbreaking research in multiple sclerosis and psoriatic arthritis treatments, evaluating novel therapeutic approaches including BTK inhibitors and biological treatments.

  • Progressive MS treatment development
  • Arthritis management innovations
  • Long-term therapy effectiveness

Focus on improving quality of life and disease management for patients with chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.